Jason Portis assists clients with their domestic and international IP portfolios. He has experience in multiple industries including pharmaceuticals, gene therapeutics, plastics, medical devices, semiconductors, nanoparticles, and pre-fabricated building materials for clients ranging from startups to industry leaders. Jason provides his clients with focused strategies for protecting and developing intellectual property to achieve their technological and commercial goals.
Jason counsels clients on IP strategy including patent infringement, validity, and freedom-to-operate. He also manages patent prosecution for a variety of industries, especially those in the chemical and biotechnological sectors. His work includes advising clients on strategies for drafting and prosecuting patents before the United States Patent and Trademark Office (USPTO).
Additionally, Jason assists clients with contested proceedings before the USPTO. He draws from his experience not only in proceedings before the USPTO, but also his experience in patent litigation at both the trial and appellate level. Jason works to find favorable and efficient resolutions to contested patent disputes that comprehensively address a client’s business needs.
Prior to joining BoMc, Jason worked for a nationally-recognized firm assisting clients with IP preparation, prosecution, and litigation matters. Before attending law school, Jason spent several years in cross-disciplinary research, assisting leaders in agricultural science, cancer genetics, and chemical engineering to investigate their field.
- Managed international patent families for Fortune 500 pharmaceutical, gene therapeutics, and chemical manufacturers.
- Successfully developed and implemented a multi-faceted strategy for IP protection for a startup enterprise before product launch.
- Represented a large international company in a series of related inter partes review proceedings.
- District of Columbia
- U.S. Patent and Trademark Office
- Northwestern University School of Law, J.D., 2016
- Michigan State University, B.S., Genomics & Molecular Genetics, 2013
- Michigan State University, B.S., Chemistry, 2013
- Co-author. “Palmitate-Induced IRE1–XBP1–ZEB Signaling Represses Desmoplakin Expression and Promotes Cancer Cell Migration,” co-authored with Aritro Nath, Amrita Oak, et al., Molecular Cancer Research, December 1, 2020. DOI: 10.1158/1541-7786.MCR-19-0480.
- Author. “USPTO Offers Deferred-Fee Pilot Program for COVID-19 Provisional Applications,” BoMc Blog, October 13, 2020.
- Author. “PTAB Publishes AIA Trial Practice Guide Update,” BoMc Blog, October 4, 2018.